Not all patients respond to immunotherapy equally. Factors such as genetic makeup, tumor type, and the presence of specific biomarkers can influence treatment efficacy. Epidemiological studies help identify which subgroups of the population are most likely to benefit, aiding in the optimization of treatment protocols and reducing unnecessary exposure to non-responders.